Skip to content

Three things we are watching

Tariff rollback: 2026 could be the year where US President Trump rolls back his punitive tariffs to a baseline of 10%. Under pressure from elevated food prices, the United States has already announced cuts to tariffs on agricultural imports from Argentina and Brazil. Emerging markets (EMs) could be the primary beneficiaries of a broadening in this pivot in 2026, given they were among the countries hardest hit by tariffs in the Liberation Day announcement.

India/US trade deal by year-end: The United States is expected to announce the completion of its Framework Trade Deal with India by the end of December. This is expected to reduce the current 50% tariffs on India’s exports to the United States to 10%-15%. However, agreement on the more ambitious Bilateral Trade Agreement (BTA), which is expected to include a lowering of India’s tariff and non-tariff barriers for US agricultural exports, remains a challenge. Aside from reducing barriers to agricultural imports, the goal of the BTA is to increase US/India trade in goods and services from US$210 billion in 2024 to US$300 billion by 2030.1

Russia-Ukraine peace deal. Expectations of a peace deal between Russia and Ukraine have increased following the leak of the 28-point peace plan created by US negotiators. If a peace deal is successful, it could exert downward pressure on energy and agricultural commodity prices, given the importance of Russia and Ukraine exports of crude oil, gas, wheat and oil seeds. Lower commodity prices would be positive for inflation in developed markets, creating scope for additional interest-rate cuts in 2026. This could result in further US-dollar weakness, which would be positive for emerging markets.

Outlook

Chinese equities received a recent boost from the country’s anti-involution push, which aims to reduce price competition and industrial overcapacity. Manufacturing and high-technology sectors were focal points of this movement, which became formal and expanded during 2025. The investment team met with some strategic advisors to glean more insight into this reform.

A central objective of the anti-involution push is to generate additive innovation. In a hyper‑competitive environment, price wars and constant defensive spending erode profit margins across an industry, including for market leaders. By contrast, policymakers prefer a smaller number of financially stronger champions in each sector, rather than many weaker players, so that leading companies can reinvest their profits in innovation and research and development, reinforcing China’s broader industrial ecosystem.

Translating this objective into measurable outcomes is challenging because there is no formal metric system, but several indicators offer useful clues. Rising profitability among industry leaders is one sign, while broader margin improvement across entire supply chains is another. Greater international competitiveness would also signal progress: As Chinese firms move up the value chain, more “national champions” may emerge in advanced manufacturing, shifting from volume-driven growth toward higher-value, innovation-led offerings. For example, contract manufacturers could develop proprietary technologies and e-commerce platforms could expand into areas such as cloud computing.

There are also more ambiguous measures of success. Over time, improvements in overall well‑being, consumer confidence and even birth rates could suggest that the pressure of involution is easing and that the nation is sharing economic gains more sustainably.

The risk of a less successful anti-involution policy may have implications for investors worldwide. Continuous profit pressures and misallocation of capital may have negative implications, given China’s central role in many supply chains. However, China’s policies are greatly tied to national priorities. As investors in Chinese equities, our investment process has a top-down overlay to cater to the importance of policy direction in the country. Our China equity funds also favour leaders in their respective industries, as these companies also offer their own competitive advantages. We therefore believe that the anti-involution movement may provide a boost to well-managed companies with sustainable competitive advantages.

EMs are not homogenous, hence there will be different opportunities across the asset class. Our access to industry experts, company management and other sources of information provide us with the ability to balance optimism with risks.

Market review: November 2025

EM equities slid in November 2025. Pessimism over the odds of a US interest-rate reduction in December put a cap on performance. Concerns regarding stretched valuations in artificial intelligence (AI)-related stocks also pressured global indexes. For the month, the MSCI EM Index returned -2.38%, while the MSCI World Index delivered 0.31%.

The emerging Asia region declined, with most countries reporting losses. Technology stocks in South Korea and Taiwan took heed from global sentiment and weakened from concerns over equity valuations. Also in South Korea, the market regulator’s rare caution over the share price rally of a semiconductor company hurt equities. In China, rising geopolitical tensions, this time between China and Japan, had impact on the equity market.

However, Indian equities rose. Market sentiment was largely positive, with cooling local inflation, encouraging progress toward a US-India trade deal and lower oil prices. Corporate earnings were largely positive, which also helped to buoy Indian equities upward.

Equities in the emerging Europe, Middle East and Africa region also retreated, taking cues from global markets. Weaker oil prices dampened investor sentiment for Middle Eastern equities, with disappointing corporate earnings in Saudi Arabia adding to subdued equity performance. South African equities, however, bucked the regional trend and ended higher over stronger national growth prospects and an improving fiscal outlook.

Equities in the emerging Latin America (LatAm) region advanced as a whole. An upswing in Brazilian equities supported regional performance. Lower-than-expected inflation statistics for October 2025 paved hopes that an easing cycle may be on the cards soon. Annual inflation for Mexico also decelerated in October, and the Mexican central bank reduced its benchmark interest rate further. The rate now stands at 7.25%, the lowest level since May 2022.



IMPORTANT LEGAL INFORMATION

This material is intended to be of general interest only and should not be construed as individual investment advice or a recommendation or solicitation to buy, sell or hold any security or to adopt any investment strategy. It does not constitute legal or tax advice. This material may not be reproduced, distributed or published without prior written permission from Franklin Templeton.

The views expressed are those of the investment manager and the comments, opinions and analyses are rendered as at publication date and may change without notice. The underlying assumptions and these views are subject to change based on market and other conditions and may differ from other portfolio managers or of the firm as a whole. The information provided in this material is not intended as a complete analysis of every material fact regarding any country, region or market. There is no assurance that any prediction, projection or forecast on the economy, stock market, bond market or the economic trends of the markets will be realized. The value of investments and the income from them can go down as well as up and you may not get back the full amount that you invested. Past performance is not necessarily indicative nor a guarantee of future performance. All investments involve risks, including possible loss of principal.

Any research and analysis contained in this material has been procured by Franklin Templeton for its own purposes and may be acted upon in that connection and, as such, is provided to you incidentally. Data from third party sources may have been used in the preparation of this material and Franklin Templeton ("FT") has not independently verified, validated or audited such data.  Although information has been obtained from sources that Franklin Templeton believes to be reliable, no guarantee can be given as to its accuracy and such information may be incomplete or condensed and may be subject to change at any time without notice. The mention of any individual securities should neither constitute nor be construed as a recommendation to purchase, hold or sell any securities, and the information provided regarding such individual securities (if any) is not a sufficient basis upon which to make an investment decision. FT accepts no liability whatsoever for any loss arising from use of this information and reliance upon the comments, opinions and analyses in the material is at the sole discretion of the user.

Franklin Templeton has environmental, social and governance (ESG) capabilities; however, not all strategies or products for a strategy consider “ESG” as part of their investment process.

Products, services and information may not be available in all jurisdictions and are offered outside the U.S. by other FT affiliates and/or their distributors as local laws and regulation permits. Please consult your own financial professional or Franklin Templeton institutional contact for further information on availability of products and services in your jurisdiction.

Issued in the U.S. by Franklin Templeton, One Franklin Parkway, San Mateo, California 94403-1906, (800) DIAL BEN/342-5236, franklintempleton.com. Investments are not FDIC insured; may lose value; and are not bank guaranteed.

You need Adobe Acrobat Reader to view and print PDF documents. Download a free version from Adobe's website.

CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.